Case Report: Lymphohistiocytic Myocarditis With Severe Cardiogenic Shock Requiring Mechanical Cardiocirculatory Support in Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection

Xavier Bemtgen 1,2*, Karin Klingel 3, Markus Hufnagel 4, Ales Janda 5, Christoph Bode 1,2, Dawid L. Staudacher 1,2, Alexander Supady 1,5,6 and Ilona Jandova 7

1 Department of Cardiology and Angiology I (Heart Center Freiburg – Bad Krozingen), University Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2 Department of Medicine III (Interdisciplinary Medical Intensive Care), University Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 3 Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany, 4 Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, 5 Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany, 6 Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany, 7 Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Multisystem Inflammatory Syndrome (MIS) is a novel hyperinflammatory syndrome associated with SARS-CoV-2 infection. It predominantly affects children (MIS-C) a few weeks after a usually asymptomatic SARS-CoV-2 infection and is only rarely seen in adults above 21 years (MIS-A). Only scarce data on histological findings in both pediatric and adult patients has been published so far. An 18-year-old male patient was admitted to hospital in a febrile state, which progressed to severe cardiogenic shock and multi-organ failure requiring extracorporeal life support. Myocardial biopsy revealed small vessel-associated immune cell infiltrates. Diagnosis of MIS-C was made after ruling out all potential differential diagnosis. Use of immunosuppressive treatment with steroids, interleukin-1 blockade and high-dose intravenous immunoglobulins resulted in the patient’s full recovery. Multisystem Inflammatory Syndrome (MIS) is a new differential diagnosis of cardiac dysfunction in pediatric and adult patients. The lack of myocardial necrosis differentiates the disease from other viral myocarditis and offers an explanation for the fast response to immunomodulatory therapy and the favorable prognosis. The preceding SARS-CoV-2 infection might only have been mildly symptomatic or even asymptomatic.

Keywords: COVID-19, V-A ECMO, Impella®, MIS-C, Multisystem Inflammatory Syndrome in children, myocardial biopsy
INTRODUCTION

Coronavirus disease 2019 (COVID-19) with respiratory failure is the primary complication of an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults. Here, diagnosis and treatment is progressively better understood (1). In pediatric patients however, a novel hyperinflammation syndrome called Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious pathology caused by a SARS-CoV-2 infection (2). The awareness and knowledge on this hyperinflammation syndrome are steadily growing among pediatricians, but the more uncommon adult variant of this syndrome, Multisystem Inflammatory Syndrome in Adults (MIS-A), is widely unknown in adult medicine. The threshold between the pediatric and the adult variant is 21 years as defined by the CDC (3). Only scarce data on histological findings in both pediatric and adult patients has been published so far.

Here, we report the case of a young adult with severe cardiogenic shock diagnosed with severe MIS-C backed by myocardial biopsy and rapid recovery following initiation of immunosuppressive treatment.

CASE DESCRIPTION

An 18-year-old male patient presented to the emergency department with hyperpyrexia (42°C), chills and tachycardia. Physical examination and chest X-ray revealed no pathological findings. Laboratory tests showed elevated C-reactive protein (CRP; 105.9 mg/l, reference range <5 mg/l) as well as interleukin 6 serum levels (IL-6; 128 pg/ml, reference range <7 pg/ml), but only modestly elevated procalcitonin (PCT; 0.12 ng/ml, reference range <0.05 ng/ml) (Figure 1). The patient was admitted to a standard care ward and an empiric antibiotic therapy was initiated.

The patient’s medical history was unremarkable. Approximately 2 months prior to admission, the patient was exposed to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and went into quarantine. A few days after this exposure, he complained he had lost his sense of smell, but he experienced no other symptoms. Neither during his quarantine nor after his initial admission to the hospital was quarantined nor after his initial admission to the hospital was he diagnosed with respiratory failure. A general rash affecting the abdomen and all limbs occurred. On day 4 following hospital admission, transthoracic echocardiography revealed a severely impaired left ventricular cardiac function (left ventricular ejection fraction, LVEF, 25%, Supplementary Video 1). No relevant ECG pathologies were seen beside sinus tachycardia. At that time, Pulse Contour Cardiac Output (PiCCO; Getinge, Rastatt, Germany) measurement confirmed marginal cardiac output of 4.4 l/min (reference range: 4–8 l/min). Computed tomography showed enlarged abdominal lymph nodes, wall thickening of the colon and polyserositis with pericardial and pleural effusions and ascites. Respiratory failure due to pulmonary edema required non-invasive ventilation (NIV).

Subsequently, on day 4 after hospital admission, liver and renal failure and massive systemic inflammatory response became evident (Figure 1). The rheumatology workup (anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), anti-neutrophil cytoplasmic antibodies (ANCA), anti-phospholipid antibodies, complement) were unremarkable. Microbiological investigation only revealed positive SARS-CoV-2 serology (anti-S1 and anti-N antibodies).

Four days after initial hospital admission, the patient was transferred to our hospital, a tertiary care center in Freiburg, Germany. Upon admission, levosimendan was initiated in order to improve cardiac output. The following day, endomyocardial biopsy (EMB) was performed. Signs of hypoperfusion and organ failure persisted (elevated lactate, renal function, Figure 1). For this reason, a percutaneous ventricular assist device (Impella®, Abiomed, Danvers, NJ, United States of America) was implanted. Subsequently, cardiac output improved from 3.6 to 4.9 l/min and pulmonary capillary wedge pressure decreased from 26 to 21 mmHg.

However, due to both progressive hypoxemia under NIV with a required fraction of inspired oxygen (FiO2) of up to 100% and to worsening neurological symptoms (sopor), invasive mechanical ventilation was indicated. Within just a few hours after endotracheal intubation, additional venoarterial extracorporeal membrane oxygenation (V-A ECMO) support was required, because of worsening hypoperfusion and severe end-organ failure (Figure 1). EMB showed a significant infiltration of immune cells into the heart. Especially CD68+ macrophages but also CD3+ T cells were found to be located primarily around small vessels within the myocardium, as shown by immunohistochemical stainings (see circle). Masson Trichrome and HE stainings further demonstrated the presence of peri紧张性纤维化 in serial tissue sections, but no myocyte necrosis (Figures 2A–D, see circle). Nested (RT-) PCR for the detection of enteroviruses (including cossackie viruses of group A and B, echoviruses, parvovirus B19, human herpesvirus 6, Epstein Barr Virus, adenoviruses, human cytomegalovirus, herpes simplex virus type 1 and 2, human herpes virus 7 (HHV7), varicella zoster virus, influenza A and B viruses, Toxoplasma gondii or borella spp. was negative in the myocardium and EDTA blood.

Abbreviations: ACR, American College of Rheumatology; ANA, Anti-nuclear antibody; ANCA, Anti-neutrophil cytoplasmic antibodies; CD, cluster of differentiation; CDC, Centers for Disease Control and Prevention; CRP, C-reactive protein; EMB, endomyocardial biopsy; ENA, Extractable nuclear antigen; FiO2, fraction of inspired oxygen; HE, hematoxylin-eosin; ICU, Intensive care unit; IL-1, interleukin 1; IL-6, interleukin 6; IVIG, intravenous immunoglobulin; LVEF, left ventricular ejection fraction; MIS-C, Multisystem Inflammatory Syndrome in Children; MIS-A, Multisystem Inflammatory Syndrome in Adults; NIV, non-invasive ventilation; PCT, procalcitonin; PiCCO, Pulse Contour Cardiac Output; PIMS-TS, Pediatric Inflammatory Multisystem Syndrome temporarily associated with SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; V-A ECMO, venoarterial extracorporeal membrane oxygenation; WHO, World Health Organization.
In addition, qRT-PCR did not detect SARS-CoV-2 RNA in the myocardium.

Following interdisciplinary discussion (pediatrics, rheumatology, cardiology, and infectious disease), Multisystem Inflammatory Syndrome in children (MIS-C) following preceding SARS-CoV-2 infection was diagnosed and immunosuppressive therapy including high-dose intravenous immunoglobulin (IVIG), dexamethasone and IL-1-blockade (anakinra) was initiated (Figure 1). Clinical and laboratory parameters improved within 3 days and 1 day, respectively (Figure 1). As cardiac function recovered, this enabled discontinuation of extracorporeal cardiocirculatory support (V-A ECMO, Impella®) on day seven after initiation. Cardiac necrosis parameters were only moderately elevated during the shock phase (max. TroponinI 341 ng/L, ref <14 ng/L; CK-MB max 54 U/L, ref < 24 U/L) indicating only a minor myocardial damage has occurred. Cardiac function did indeed fully recover (Supplementary Video 2). Renal function only was able to fully recover after 30 days to full recovery. The patient was able to be discharged 32 days after initial hospital admission.

DISCUSSION

Early during the SARS-CoV-2 pandemic, a novel hyperinflammatory syndrome was described. Initially, only pediatric cases were identified with symptoms and clinical findings, which in many respects resembled features of Kawasaki disease and Toxic Shock Syndrome (4, 5). Two synonymic terms—Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric Inflammatory Multisystem Syndrome temporarily associated with SARS-CoV-2 (PIMS-TS)—were established (3, 6, 7). Later, a similar syndrome was reported in adults (MIS-A) (8, 9).

Our patient fulfilled the diagnostic criteria of MIS-C with fever, rash, lymphadenopathy, shock, myocardial injury, colitis, and positive SARS-CoV-2 serology, as well as severe inflammatory response. For this reason, immunomodulatory therapy based on clinical recommendations of the American College of Rheumatology (ACR) was initiated (3).

ACR recommends steroid treatment with methylprednisolone (20–30 mg/kg a day, for 1–3 days up to 1 g per day followed by tapering doses—2 mg/kg a day, maximum 60 mg a day);
high-dose intravenous immune globulin therapy (2 g/kg a dose) in moderate to severe cases; and cytokine receptor (IL-1 or IL-6) blockade (3).

As with myocardial involvement following other viral infections, cardiac injury in MIS-C may occur either due to direct cardiac invasion by the virus (10–13) or else following accompanying cytokine storm (2). Since EMB is only rarely performed, the reported cases of myocardial injury in the context of the SARS-CoV-2 infection are largely based upon clinical symptoms, laboratory results and imaging findings (e.g., electro- and echocardiography, magnetic resonance). Arrhythmias, decreased LVEF and high prevalence of cardiogenic shock were reported (14). Histopathological investigations of EMB in patients with COVID-19 revealed multi-focal lymphocytic and interstitial macrophage infiltrates (15) without substantial myocyte necrosis. Despite the fact that SARS-CoV-2 can infect macrophages but also myocytes (16), this virus is obviously not cytolytic as e.g., coxsackievirus B3 (17). So far, the exact molecular mechanisms by which the infiltration of many macrophages and less T cells are induced in MIS patients are not known. It is likely that SARS-CoV-2 rather induces an inflammatory response by cytokine release, thus resulting in a kind of indirect myocardial injury (18). Further investigations are required to investigate why in MIS patients but not in other patients with myocardial SARS-CoV-2 infections the inflammation is associated with the vessels (19). It has to be discussed whether the presence of extensive perivascular lympho-histiocytic infiltrates without myocyte necrosis may explain the rapid response to immunosuppressive therapy in our patient. This is similar to other reported cases (9, 14, 20).
CONCLUSION

Even following asymptomatic SARS-CoV-2 infection, children and young adults may develop severe Multisystem Inflammatory Syndrome in Children or Adults (MIS-C/A). In our case report, myocardial involvement (verified by endomyocardial biopsy) caused severe cardiogenic shock requiring medical as well as mechanical cardiocirculatory support. Early immunomodulatory treatment with glucocorticoids, intravenous immunoglobulin and cytokine receptor blockade helped control symptoms and interrupt uncontrolled inflammatory response. The patient’s cardiac function recovered after 7 days on mechanical cardiocirculatory support with Impella® and V-A ECMO. Prompt diagnosis of MIS-C is critical, as swift use of intense immunosuppressive therapy may lead to a better prognosis for the patient. Therefore, we advise critical care clinicians to consider this differential diagnosis early on when confronted with patients suffering from severe inflammatory response and impaired cardiac function.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author(s).

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

REFERENCES

1. Izda V, Jeffries MA, Sawalha AH. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin Immunol. (2021) 222:108634. doi: 10.1016/j.clim.2020.108634
2. Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell. (2020) 183:982–95.e14. doi: 10.1016/j.cell.2020.09.034
3. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol. (2021) 73:41616. doi: 10.1002/art.41616
4. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocaris P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. (2020) 395:1607–8. doi: 10.1016/S0140-6736(20)31094-1
5. Toubiana J, Poirault C, Corsia A, Bajolle F, Angou lvant F, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol. (2021) 73:41616. doi: 10.1002/art.41616
6. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBE, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. (2020) 383:334–46. doi: 10.1056/NEJMoa2021680
7. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. J Am Med Assoc. (2020) 324:259. doi: 10.1001/jama.2020.10369
8. Morris SB. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection — United Kingdom and United States, March–August 2020. Morb Mortal Wkly Rep. (2020) 69:40e1. doi: 10.15585/mmwr.mm6940e1
9. Bastug A, Aslaner H, Aybar Bilir Y, Kemirtlek N, Gursoy FM, Bastug S, et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Rheumatol Int. (2021) 41:993–1008. doi: 10.1007/s00296-021-04843-1
10. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. (2020) 22:911–5. doi: 10.1002/ejhf.1828
11. Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. (2020) 7:2440–7. doi: 10.1002/ehf2.12805
12. Wenzel P, Kopp S, Göbel S, Jansen T, Geyer M, Hahn F, et al. Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab. Cardiovasc Res. (2020) 116:1661–3. doi: 10.1093/cvr/cvaa160
13. Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients

AUTHOR CONTRIBUTIONS

XB, AS, and IJ conceived and designed the case report, collected the data, and wrote the manuscript. KK contributed to the pathology diagnosis. JJ, MH, DS, and AJ contributed to the clinical diagnosis. CB supervised the conception, analysis, design of the work, and manuscript drafting. All authors critically revised the manuscript for important intellectual content and provided approval of the final version.

FUNDING

This work was supported by Deutsche Herzstiftung COVID-19. The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing.

ACKNOWLEDGMENTS

A sincere thank you to Natalie Diffloth for her diligent proofreading of this paper.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.716198/full#supplementary-material

Supplementary Video 1 | Apical 4 chamber view at admission. Severely impaired left ventricular function seen directly after admission to our hospital.

Supplementary Video 2 | Apical 4 Chamber view after recovery. Fully recovered function seen 2 days after V-A ECMO and Impella® explantation.
with COVID-19: a prospective cohort study. Ann Intern Med. (2020)
173:268–77. doi: 10.7326/L20-1206

14. Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A,
    Di Filippo S, et al. Acute cardiovascular manifestations in 286 children
    with multisystem inflammatory syndrome associated with COVID-19
    infection in Europe. Circulation. (2021) 143:21–32. doi: 10.2139/ssrn.363
    4853

15. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal AC, Aubry
    M-C, et al. Pathological features of COVID-19-associated myocardial
    injury: a multicentre cardiovascular pathology study. Eur Heart J. (2020)
    41:3827–35. doi: 10.1093/eurheartj/ehaa664

16. Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem
    U, Hansen A, et al. SARS-CoV-2 infects and induces cytotoxic
    effects in human cardiomyocytes. Cardiovasc Res. (2020)
    116:2207–15. doi: 10.1093/cvr/cvaa267

17. Klingel K, Pöml P, Strunk J, Werthmann M-L. Lethal enterovirus
    myocarditis in a patient with granulomatosis with polyangiitis
    following rituximab and high-dose steroid therapy. Eur Heart J. (2021)
    42:2401. doi: 10.1093/eurheartj/ehab269

18. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner
    K, et al. Association of cardiac infection with SARS-CoV-2 in
    confirmed COVID-19 autopsy cases. J Am Med Assoc Cardiol. (2020)
    5:1281. doi: 10.1001/jamacardio.2020.3551

19. Greulich S, Klingel K. COVID-19 and myocarditis: findings from cardiac
    magnetic resonance imaging and endomyocardial biopsies. Hamostaseologie.
    (2021) 14:8664. doi: 10.1055/a-1539-8664

20. Bajaj R, Sinclair HC, Patel K, Low B, Pericao A, Manisty C, et al.
    Delayed-onset myocarditis following COVID-19. Lancet Respir Med. (2021)
    9:e32–4. doi: 10.1016/S2213-2600(21)00085-0

Conflict of Interest: AS reports research grants and lecture fees from CytoSorbents
and lecture fees from Abiomed, both outside the submitted work.

The remaining authors declare that the research was conducted in the absence
of any commercial or financial relationships that could be construed as a potential
conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.

Copyright © 2021 Bemtgen, Klingel, Hufnagel, Janda, Bode, Staudacher, Supady and
Jandova. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.